|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
8
|
|
pubmed:dateCreated |
2003-8-25
|
|
pubmed:abstractText |
BBR 2778 is a new aza-anthracenedione. Its activity against hematologic neoplasias in a mouse model is greater than that of doxorubicin or mitoxantrone. A phase-I study in patients with non-Hodgkin's lymphoma (NHL) showed that the drug has promising anti-tumor activity. Therefore, a phase-II study in patients with relapsed aggressive NHL was initiated.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1592-8721
|
|
pubmed:author |
pubmed-author:BorchmannPeterP,
pubmed-author:CamboniGabriellaG,
pubmed-author:EngertAndreasA,
pubmed-author:GüntherHansH,
pubmed-author:GisselbrechtChristianC,
pubmed-author:HarousseauJean LucJL,
pubmed-author:MorschhauserFranckF,
pubmed-author:ParryAnneA,
pubmed-author:PfreundschuhDerigs MichaelDM,
pubmed-author:RudolphChristianC,
pubmed-author:SchnellRolandR,
pubmed-author:WilhelmMartinM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
88
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
888-94
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12935976-Adult,
pubmed-meshheading:12935976-Aged,
pubmed-meshheading:12935976-Aged, 80 and over,
pubmed-meshheading:12935976-Anemia,
pubmed-meshheading:12935976-Antineoplastic Agents,
pubmed-meshheading:12935976-Drug Administration Schedule,
pubmed-meshheading:12935976-Female,
pubmed-meshheading:12935976-Humans,
pubmed-meshheading:12935976-Isoquinolines,
pubmed-meshheading:12935976-Lymphoma, Non-Hodgkin,
pubmed-meshheading:12935976-Lymphopenia,
pubmed-meshheading:12935976-Male,
pubmed-meshheading:12935976-Middle Aged,
pubmed-meshheading:12935976-Neoplasm Recurrence, Local,
pubmed-meshheading:12935976-Neutropenia,
pubmed-meshheading:12935976-Recurrence,
pubmed-meshheading:12935976-Thrombocytopenia,
pubmed-meshheading:12935976-Topoisomerase II Inhibitors,
pubmed-meshheading:12935976-Treatment Outcome
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Phase-II study of the new aza-anthracenedione, BBR 2778, in patients with relapsed aggressive non-Hodgkin's lymphomas.
|
|
pubmed:affiliation |
Klinik I für Innere Medizin der Universität zu Köln, Germany.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|
